Incyte Corp logo

Incyte Corp

$ 83.13 +2.45 (+3.04%) 10:08 PM EST
On watch
P/E:
21.15
P/B:
4.38
Market Cap:
$ 18.49B
Enterprise V:
$ 15.01B
Volume:
1.65M
Avg Vol (2M):
1.41M
Also Trade In:
Volume:
1.65M
Market Cap $:
18.49B
PE Ratio:
21.15
Avg Vol (2-Month):
1.41M
Enterprise Value $:
15.01B
PB Ratio:
4.38
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Incyte Corp ( ) from 1993 to Dec 02 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Incyte stock (INCY) PE ratio as of Dec 02 2022 is 21.15. More Details

Incyte Corp (INCY) PE Ratio (TTM) Chart

To
Not Enough Data to Display

Incyte Corp (INCY) PE Ratio (TTM) Historical Data

Total 1242
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Incyte PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-12-03 21.1 2022-09-29 16.9
2022-12-01 20.5 2022-09-28 17.2
2022-11-30 20.3 2022-09-27 15.6
2022-11-29 19.8 2022-09-26 15.6
2022-11-28 19.8 2022-09-23 15.7
2022-11-25 19.9 2022-09-22 15.9
2022-11-23 19.8 2022-09-21 15.7
2022-11-22 19.9 2022-09-20 16.1
2022-11-21 19.9 2022-09-19 16.2
2022-11-18 19.7 2022-09-16 16.2
2022-11-17 19.8 2022-09-15 16.2
2022-11-16 19.5 2022-09-14 16.1
2022-11-15 19.5 2022-09-13 16.0
2022-11-14 19.6 2022-09-12 16.6
2022-11-11 19.7 2022-09-09 17.0
2022-11-10 19.8 2022-09-08 16.9
2022-11-09 19.6 2022-09-07 16.8
2022-11-08 19.5 2022-09-06 16.3
2022-11-07 19.3 2022-09-02 16.5
2022-11-04 19.7 2022-09-01 16.8
2022-11-03 19.6 2022-08-31 16.6
2022-11-02 19.6 2022-08-30 16.5
2022-11-01 19.6 2022-08-29 16.6
2022-10-31 18.9 2022-08-26 16.8
2022-10-28 19.0 2022-08-25 17.1
2022-10-27 18.5 2022-08-24 17.2
2022-10-26 18.7 2022-08-23 17.2
2022-10-25 18.4 2022-08-22 17.3
2022-10-24 18.4 2022-08-19 17.5
2022-10-21 18.0 2022-08-18 17.3
2022-10-20 17.6 2022-08-17 17.4
2022-10-19 17.7 2022-08-16 17.6
2022-10-18 18.1 2022-08-15 17.7
2022-10-17 17.9 2022-08-12 17.4
2022-10-14 17.6 2022-08-11 17.4
2022-10-13 17.4 2022-08-10 17.4
2022-10-12 17.2 2022-08-09 17.4
2022-10-11 17.1 2022-08-08 17.4
2022-10-10 17.2 2022-08-05 17.0
2022-10-07 17.4 2022-08-04 16.9
2022-10-06 17.7 2022-08-03 17.1
2022-10-05 17.7 2022-08-02 17.1
2022-10-04 17.7 2022-08-01 18.2
2022-10-03 17.5 2022-07-29 18.3
2022-09-30 17.0 2022-07-28 18.6

Incyte Corp (INCY) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.